M. Bidri and M. Arock, Différenciation des cellules hématopoïétiques : intervention des cytokines et expression des marqueurs membranaires, Rev. Fr. Allergol. Immunol. Clin, vol.36, pp.859-878, 1996.

B. Blom, H. Spits, . Development, . Human, and . Cells, Annu. Rev. Immunol, vol.24, pp.287-320, 2006.

K. L. Good-jacobson, K. O'donnell, G. T. Belz, S. L. Nutt, and D. M. Tarlinton, c-Myb is required for plasma cell migration to bone marrow after immunization or infection, J. Exp. Med, vol.212, pp.1001-1009, 2015.

H. W. Schroeder and L. Cavacini, Structure and Function of Immunoglobulins, J. Allergy Clin. Immunol, vol.125, pp.41-52, 2010.

S. V. Rajkumar, International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol, vol.15, pp.538-548, 2014.

R. A. Kyle, Prevalence of monoclonal gammopathy of undetermined significance, N. Engl. J. Med, vol.354, pp.1362-1369, 2006.

R. A. Kyle and S. V. Rajkumar, Monoclonal gammopathy of undetermined significance, Br. J. Haematol, vol.134, pp.573-589, 2006.
URL : https://hal.archives-ouvertes.fr/hal-00945713

R. A. Kyle, Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma, N. Engl. J. Med, vol.356, pp.2582-2590, 2007.

R. L. Siegel, K. D. Miller, and A. Jemal, Cancer statistics, 2019. CA, Cancer J. Clin, vol.69, pp.7-34, 2019.

, Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2012: étude à partir des registres des cancers du réseau Francim, 2013.

R. A. Kyle, Review of 1027 patients with newly diagnosed multiple myeloma, Mayo Clin. Proc, vol.78, pp.21-33, 2003.

D. D. Alexander, Multiple myeloma: A review of the epidemiologic literature, Int. J. Cancer, vol.120, pp.40-61, 2007.

H. Avet-loiseau and J. Corre, Cytogénétique et génétique moléculaire du myélome multiple, Rev. Francoph. Lab, pp.50-57, 2019.

S. V. Rajkumar, Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management, Am. J. Hematol, vol.93, pp.1091-1110, 2018.

G. Bianchi and N. C. Munshi, Pathogenesis beyond the cancer clone(s) in multiple myeloma, Blood, vol.125, pp.3049-3058, 2015.

B. Bouvard, Gammapathie monoclonale de signification indéterminée, myélome multiple et ostéoporose, Rev. Rhum, vol.77, pp.144-148, 2010.

S. Roux, os du myélome multiple : physiopathologie, Rev. Rhum. Monogr, vol.84, pp.181-186, 2017.

, The International Myeloma Working Group*. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group, Br. J. Haematol, vol.121, pp.749-757, 2003.

A. Dispenzieri and R. A. Kyle, Multiple myeloma: clinical features and indications for therapy, Best Pract. Res. Clin. Haematol, vol.18, pp.553-568, 2005.

B. O. Oyajobi, Multiple myeloma/hypercalcemia, Arthritis Res. Ther, vol.9, issue.1, p.4, 2007.

, Hyperviscosity Syndrome in Plasma Cell Dyscrasias. Semin. Thromb. Hemost, vol.29, pp.467-472, 2003.

A. Dispenzieri and R. A. Kyle, Neurological aspects of multiple myeloma and related disorders, Best Pract. Res. Clin. Haematol, vol.18, pp.673-688, 2005.

S. S. Chawla, Clinical course and prognosis of non-secretory multiple myeloma, Eur. J. Haematol, vol.95, pp.57-64, 2015.

A. Daudignon, Cytogenetics in the management of multiple myeloma: an update by the Groupe francophone de cytogénétique hématologique (GFCH), Ann. Biol. Clin, pp.588-595, 20169.

M. Chesi and P. L. Bergsagel, Molecular pathogenesis of multiple myeloma: basic and clinical updates, Int. J. Hematol, vol.97, pp.313-323, 2013.

A. Palumbo, Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group, J. Clin. Oncol, vol.33, pp.2863-2869, 2015.

J. Caers, Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel, J. Hematol. Oncol.J Hematol Oncol, vol.11, 2018.

A. Jaccard, E. Desport, D. Mohty, F. Bridoux, A. L. Amylose et al., Médecine Interne, vol.36, pp.89-97, 2015.

M. Gavriatopoulou, European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias, Leukemia, 2018.

J. Li and D. Zhou, New advances in the diagnosis and treatment of POEMS syndrome, Br. J. Haematol, vol.161, pp.303-315, 2013.

, the International Myeloma Working Group et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group, vol.27, pp.780-791, 2013.

B. Ribourtout and M. Zandecki, Plasma cell morphology in multiple myeloma and related disorders, Morphologie, vol.99, pp.38-62, 2015.

L. Nadav, Diverse niches within multiple myeloma bone marrow aspirates affect plasma cell enumeration, Br. J. Haematol, vol.133, pp.530-532, 2006.

M. Oyaert, M. Delforge, and N. Boeckx, Use of multiparameter flow cytometry in multiple myeloma and other plasma cell neoplasms, Belg. J. Hematol, vol.6, pp.46-53, 20150501.

T. Dejoie, D. Lakomy, H. Caillon, B. Pegourié, and O. Decaux, IFM (Intergroupe francophone du myélome) recommendations for uniform interpretation of serum and urine protein electrophoresis in multiple myeloma diagnosis and follow-up, Ann. Biol. Clin, pp.429-441

H. Ludwig, International Myeloma Working Group recommendations for global myeloma care, Leukemia, vol.28, pp.981-992, 2014.

J. B. Oudart, Urinary investigations in the diagnosis and monitoring of monoclonal gammopathies in daily practice, Ann. Biol. Clin, pp.147-152

C. Camaré and E. Caussé, Urinary protein electrophoresis, which analysis to select? A simplified interpretation, Ann. Biol. Clin, pp.667-678, 201311.

A. Corso, S. Mangiacavalli, . Non-secretory, and . Myeloma, READY FOR A NEW DEFINITION?, Mediterr. J. Hematol. Infect. Dis, vol.9, p.2017053, 2017.

, International Myeloma Working Group27 et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders, Leukemia, vol.23, pp.215-224, 2009.

A. Bidet, G. Marit, and A. M. Bérard,

, Ann. Biol. Clin, vol.66, pp.427-431, 2008.

S. Kumar, International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, Lancet Oncol, vol.17, pp.328-346, 2016.

M. Laforet, Evolution in the treatment of multiple myeloma and impact on dialysis independence: data from a French cohort from 1999 to 2014, Blood Cancer J, vol.6, pp.409-409, 2016.

W. I. Gonsalves, Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement, Bone Marrow Transplant, vol.54, pp.353-367, 2019.

S. V. Rajkumar, Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1, Blood, vol.117, pp.4691-4695, 2011.

K. A. Frerichs, CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience, Expert Rev. Clin. Immunol, vol.14, pp.197-206, 2018.

S. Z. Usmani, Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma, Blood, vol.134, pp.668-677, 2019.

P. L. Clemens, Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment, Clin. Pharmacokinet, vol.56, pp.915-924, 2017.

M. Ovacik and K. Lin, Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development: Tutorial on Monoclonal Antibody Pharmacokinetics, vol.11, pp.540-552, 2018.

X. S. Xu, Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma, Adv. Ther, vol.35, pp.1859-1872, 2018.

P. Moreau, Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma, Drugs, vol.76, pp.853-867, 2016.

H. A. Blair, Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma, Drugs, vol.77, pp.2013-2024, 2017.

N. W. Van-de-donk, Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma, Blood, vol.127, pp.681-695, 2016.

A. S. Rosenberg, S. Bainbridge, R. Pahwa, and I. Jialal, Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay, Clin. Biochem, vol.49, pp.1202-1204, 2016.

N. W. Van-de-donk, Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA), Clin. Chem. Lab. Med. CCLM, vol.54, 2016.

A. Oberle, Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection, Haematologica, vol.102, pp.368-370, 2017.

I. S. Nijhof, CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma, Blood, vol.128, pp.959-970, 2016.

É. Rabut, A. Castro-fernandez, V. Le-gall, and N. Meknache, Case report: serological testing interference of daratumumab (anti-CD38) therapy in multiple myeloma, Ann. Biol. Clin, vol.75, pp.351-355, 2017.

V. Deneys, Daratumumab: Therapeutic asset, biological trap! Transfus, Clin. Biol, vol.25, pp.2-7, 2018.

C. Mccudden, Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference, Clin. Chem. Lab. Med. CCLM, vol.54, 2016.

H. Caillon, Overcoming the Interference of Daratumumab with Immunofixation Electrophoresis (IFE) Using an Industry-Developed Dira Test : Hydrashift 2/4 Daratumumab, Blood, vol.128, pp.2063-2063, 2016.

K. L. Thoren, M. J. Pianko, Y. Maakaroun, C. O. Landgren, and L. V. Ramanathan, Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay, J. Appl. Lab. Med, vol.3, pp.857-863, 2019.

J. R. Mills and D. L. Murray, Identification of Friend or Foe: The Laboratory Challenge of Differentiating M-Proteins from Monoclonal Antibody Therapies, J. Appl. Lab. Med. AACC Publ, vol.1, pp.421-431, 2017.

. Serment-de-galien,

, Je jure, en présence des Maîtres de la Faculté

, D'honorer ceux qui m'ont instruit dans les préceptes de mon art et de leur témoigner ma reconnaissance en restant fidèle à leur enseignement

, intérêt de la santé publique, ma profession avec conscience et de respecter non seulement la législation en vigueur, mais aussi les règles de l'honneur

, De ne jamais oublier ma responsabilité et mes devoirs envers le malade et sa dignité humaine, de respecter le secret professionnel

, En aucun cas, je ne consentirai à utiliser mes connaissances et mon état pour corrompre les moeurs et favoriser des actes criminels

, Que les hommes m'accordent leur estime si je suis fidèle à mes promesses

, Que je sois couvert d'opprobre et méprisé de mes confrères si j'y manque